| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other (expense), net | -2,038 | -470 | ||
| Net loss | -10,083 | -10,561 | ||
| Foreign currency translation adjustment | 39 | 74 | ||
| Comprehensive loss | -10,044 | -10,487 | ||
| Net loss per common share, basic (in dollars per share) | -0.6 | -0.66 | ||
| Net loss per common share, diluted (in dollars per share) | -0.6 | -0.66 | ||
| Weighted average common shares and pre-funded warrants outstanding, basic (in shares) | 16,692,476 | 16,059,423 | ||
| Weighted average common shares and pre-funded warrants outstanding, diluted (in shares) | 16,692,476 | 16,059,423 | ||
Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc. (ELTX)